CORT
Corcept Therapeutics Incorporated
Biotechnology
Market Cap$5.48B
5Y Perf.+237.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CORT vs PRGO
Revenue, margins, valuation, and 5-year total return — side by side.
PRGO
Perrigo Company plc
Drug Manufacturers - Specialty & Generic
Market Cap$1.61B
5Y Perf.-78.6%
CORT vs PRGO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CORT | PRGO |
|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| Market Cap | $5.48B | $1.61B |
| Revenue (TTM) | $769M | $4.18B |
| Net Income (TTM) | $48M | $-1.82B |
| Gross Margin | 98.3% | 34.2% |
| Operating Margin | -1.1% | -4.1% |
| Forward P/E | 136.0x | 5.6x |
| Total Debt | $6M | $3.97B |
| Cash & Equiv. | $120M | $532M |
CORT vs PRGO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CORT
PRGO
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Corcept Therapeutic… (CORT) | 100 | 337.2 | +237.2% |
| Perrigo Company plc (PRGO) | 100 | 21.4 | -78.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CORT vs PRGO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CORT leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Perrigo Company plc is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
CORT
Corcept Therapeutics Incorporated
The Growth Play
CORT carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 12.8%, EPS growth -33.3%, 3Y rev CAGR 23.7%
- 9.3% 10Y total return vs PRGO's -77.7%
- Lower volatility, beta 1.78, Low D/E 0.9%, current ratio 2.92x
Best for: growth exposure and long-term compounding
PRGO
Perrigo Company plc
The Income Pick
PRGO is the clearest fit if your priority is income & stability and defensive.
- Dividend streak 10 yrs, beta 1.18, yield 9.8%
- Beta 1.18, yield 9.8%, current ratio 2.76x
- Lower P/E (5.6x vs 136.0x)
Best for: income & stability and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CORT | 12.8% revenue growth vs PRGO's -2.8% |
| Value | PRGO | Lower P/E (5.6x vs 136.0x) |
| Quality / Margins | CORT | 6.2% margin vs PRGO's -43.5% |
| Stability / Safety | PRGO | Beta 1.18 vs CORT's 1.78 |
| Dividends | PRGO | 9.8% yield; 10-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | CORT | -27.5% vs PRGO's -51.2% |
| Efficiency (ROA) | CORT | 5.8% ROA vs PRGO's -19.8%, ROIC 6.2% vs 3.7% |
CORT vs PRGO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
CORT vs PRGO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCORTLAGGINGPRGO
PRGOPerrigo Company plc
1leads
CORTCorcept Therapeutics …
3leads
6 Total Categories
CATEGORYLEADERvs PRGOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CORT6/6
Valuation MetricsMultiples, price ratios, and targets
PRGO6/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CORT8/8
Total Returns1Y, 3Y, 5Y total returns with dividends
CORT6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CORT leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PRGO is the larger business by revenue, generating $4.2B annually — 5.4x CORT's $769M. CORT is the more profitable business, keeping 6.2% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, CORT holds the edge at +4.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CORTCorcept Therapeut… | PRGOPerrigo Company p… |
|---|---|---|
| RevenueTrailing 12 months | $769M | $4.2B |
| EBITDAEarnings before interest/tax | -$7M | $58M |
| Net IncomeAfter-tax profit | $48M | -$1.8B |
| Free Cash FlowCash after capex | $120M | $108M |
| Gross MarginGross profit ÷ Revenue | +98.3% | +34.2% |
| Operating MarginEBIT ÷ Revenue | -1.1% | -4.1% |
| Net MarginNet income ÷ Revenue | +6.2% | -43.5% |
| FCF MarginFCF ÷ Revenue | +15.6% | +2.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +4.9% | -7.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.8% | -56.4% |
CORT leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
PRGO leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than CORT's 114.9x.
| Metric | CORTCorcept Therapeut… | PRGOPerrigo Company p… |
|---|---|---|
| Market CapShares × price | $5.5B | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $5.4B | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | 62.26x | -1.14x |
| Forward P/EPrice ÷ next-FY EPS est. | 135.99x | 5.56x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 114.94x | 7.42x |
| Price / SalesMarket cap ÷ Revenue | 7.20x | 0.38x |
| Price / BookPrice ÷ Book value/share | 9.46x | 0.55x |
| Price / FCFMarket cap ÷ FCF | 38.65x | 11.12x |
PRGO leads this category, winning 6 of 6 comparable metrics.
Profitability & Efficiency
CORT leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
CORT delivers a 7.5% return on equity — every $100 of shareholder capital generates $8 in annual profit, vs $-51 for PRGO. CORT carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), CORT scores 5/9 vs PRGO's 4/9, reflecting solid financial health.
| Metric | CORTCorcept Therapeut… | PRGOPerrigo Company p… |
|---|---|---|
| ROE (TTM)Return on equity | +7.5% | -50.7% |
| ROA (TTM)Return on assets | +5.8% | -19.8% |
| ROICReturn on invested capital | +6.2% | +3.7% |
| ROCEReturn on capital employed | +6.5% | +4.3% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.01x | 1.35x |
| Net DebtTotal debt minus cash | -$114M | $3.4B |
| Cash & Equiv.Liquid assets | $120M | $532M |
| Total DebtShort + long-term debt | $6M | $4.0B |
| Interest CoverageEBIT ÷ Interest expense | — | -7.20x |
CORT leads this category, winning 8 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
CORT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CORT five years ago would be worth $24,194 today (with dividends reinvested), compared to $3,986 for PRGO. Over the past 12 months, CORT leads with a -27.5% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors CORT at 29.0% vs PRGO's -25.2% — a key indicator of consistent wealth creation.
| Metric | CORTCorcept Therapeut… | PRGOPerrigo Company p… |
|---|---|---|
| YTD ReturnYear-to-date | +33.6% | -13.5% |
| 1-Year ReturnPast 12 months | -27.5% | -51.2% |
| 3-Year ReturnCumulative with dividends | +114.9% | -58.1% |
| 5-Year ReturnCumulative with dividends | +141.9% | -60.1% |
| 10-Year ReturnCumulative with dividends | +929.2% | -77.7% |
| CAGR (3Y)Annualised 3-year return | +29.0% | -25.2% |
CORT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CORT and PRGO each lead in 1 of 2 comparable metrics.
Risk & Volatility
PRGO is the less volatile stock with a 1.18 beta — it tends to amplify market swings less than CORT's 1.78 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CORT currently trades 56.1% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CORTCorcept Therapeut… | PRGOPerrigo Company p… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.78x | 1.18x |
| 52-Week HighHighest price in past year | $91.00 | $28.44 |
| 52-Week LowLowest price in past year | $28.66 | $9.23 |
| % of 52W HighCurrent price vs 52-week peak | +56.1% | +41.2% |
| RSI (14)Momentum oscillator 0–100 | 76.9 | 60.9 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 3.4M |
Evenly matched — CORT and PRGO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CORT as "Buy" and PRGO as "Hold". Consensus price targets imply 70.6% upside for PRGO (target: $20) vs 40.4% for CORT (target: $72). PRGO is the only dividend payer here at 9.81% yield — a key consideration for income-focused portfolios.
| Metric | CORTCorcept Therapeut… | PRGOPerrigo Company p… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $71.67 | $20.00 |
| # AnalystsCovering analysts | 25 | 36 |
| Dividend YieldAnnual dividend ÷ price | — | +9.8% |
| Dividend StreakConsecutive years of raises | — | 10 |
| Dividend / ShareAnnual DPS | — | $1.15 |
| Buyback YieldShare repurchases ÷ mkt cap | +4.5% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CORT leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRGO leads in 1 (Valuation Metrics). 1 tied.
Best OverallCorcept Therapeutics Incorp… (CORT)Leads 3 of 6 categories
Loading custom metrics...
CORT vs PRGO: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is CORT or PRGO a better buy right now?
For growth investors, Corcept Therapeutics Incorporated (CORT) is the stronger pick with 12.
8% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Corcept Therapeutics Incorporated (CORT) offers the better valuation at 62. 3x trailing P/E (136. 0x forward), making it the more compelling value choice. Analysts rate Corcept Therapeutics Incorporated (CORT) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CORT or PRGO?
On forward P/E, Perrigo Company plc is actually cheaper at 5.
6x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — CORT or PRGO?
Over the past 5 years, Corcept Therapeutics Incorporated (CORT) delivered a total return of +141.
9%, compared to -60. 1% for Perrigo Company plc (PRGO). Over 10 years, the gap is even starker: CORT returned +929. 2% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CORT or PRGO?
By beta (market sensitivity over 5 years), Perrigo Company plc (PRGO) is the lower-risk stock at 1.
18β versus Corcept Therapeutics Incorporated's 1. 78β — meaning CORT is approximately 51% more volatile than PRGO relative to the S&P 500. On balance sheet safety, Corcept Therapeutics Incorporated (CORT) carries a lower debt/equity ratio of 1% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.
05Which is growing faster — CORT or PRGO?
By revenue growth (latest reported year), Corcept Therapeutics Incorporated (CORT) is pulling ahead at 12.
8% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Corcept Therapeutics Incorporated grew EPS -33. 3% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, CORT leads at 23. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CORT or PRGO?
Corcept Therapeutics Incorporated (CORT) is the more profitable company, earning 13.
1% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 13. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus 5. 9% for CORT. At the gross margin level — before operating expenses — CORT leads at 98. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CORT or PRGO more undervalued right now?
On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.
6x forward P/E versus 136. 0x for Corcept Therapeutics Incorporated — 130. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.
08Which pays a better dividend — CORT or PRGO?
In this comparison, PRGO (9.
8% yield) pays a dividend. CORT does not pay a meaningful dividend and should not be held primarily for income.
09Is CORT or PRGO better for a retirement portfolio?
For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
18), 9. 8% yield). Corcept Therapeutics Incorporated (CORT) carries a higher beta of 1. 78 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRGO: -77. 7%, CORT: +929. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CORT and PRGO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CORT is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while CORT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(CORT: 4.9% · PRGO: -7.2%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.